$NVLX - Medical Marijuana Sciences' Dr. Mark L. Ra
Post# of 63821
Posted On: 04/08/2014 9:20:04 AM
$NVLX - Medical Marijuana Sciences' Dr. Mark L. Rabe Speaks at ASA Medical Cannabis Unity Conference in Washington DC
SILVER SPRING, Md., April 8, 2014 (GLOBE NEWSWIRE) -- Medical Marijuana Sciences, Inc., a subsidiary of Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, reported today that Dr. Mark L. Rabe's presentation at the National Medical Cannabis Unity Conference, held this past weekend in Washington DC, prompted numerous questions and a lively discussion on Nuvilex's proprietary Cell-in-a-Box® platform and how Medical Marijuana Sciences is working to combine it with the cancer-fighting properties of cannabinoids.
The conference, hosted by Americans for Safe Access (ASA) and titled, "Navigating Medicinal Cannabis in the Mainstream," was attended by several hundred medical marijuana patients, parents of pediatric patients, educators, veterans, physicians, and other individuals calling for a stronger commitment to the safe, medicinal use of cannabis.
"It was a profound and humbling experience to see the dedication, commitment and sacrifice put forth by the members and sponsors of the ASA. This group of individuals has fought tirelessly to provide patients with safe access to cannabis-based medicine," said Dr. Rabe. "It was also encouraging to hear recently from the federal government comments about the potential of reclassifying or declassifying cannabis from its present status, which would provide the opportunity to advance scientific research and further the development of potentially life-saving cannabinoid-based therapies."
Dr. Rabe's presentation, "Targeted Cannabinoid-based Chemotherapy Utilizing Cell-in-a-Box® Technology," addressed new research that Medical Marijuana Sciences is undertaking in the fight against pancreatic and brain cancers and highlighted how further research is needed to help prevent the tens of thousands of deaths that occur each year as a result of these two diseases.
"Dr. Rabe is Chairman of Medical Marijuana Sciences' Scientific Advisory Board and is a well-respected veteran in the discussion of medical marijuana. His insight on the potential use of cannabinoids, particularly in combination with our parent company's Cell-in-a-Box® technology to treat these difficult cancers, has proven vital to our evolution as a company," said Tim Matula, President of Medical Marijuana Sciences. "Recent surveys have demonstrated that oncologists, among other top medical practitioners, have a keen interest in the potential use of cannabinoids both in compassionate care and in the fight against cancer and other deadly diseases; many have spoken and continue to speak openly about its decriminalization and the possible research applications that could result."
About Medical Marijuana Sciences:
Medical Marijuana Sciences, Inc. is the newest wholly-owned subsidiary of Nuvilex, Inc. It was established in early 2013 with the initial mission to develop treatments based on constituents of cannabis for two of the most serious and deadly forms of cancer, namely brain and pancreatic cancers.
(0)
(0)